Every 424B that Haoxi Health Technology Limited (HAO) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow HAO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HAO filings page.
Haoxi Health Technology Limited is conducting a primary offering of 300,000 Class A Ordinary Shares at $0.40 per share and 9,700,000 pre-funded warrants, each exercisable for one Class A Ordinary Share at an exercise price of $0.33, for gross proceeds of up to $4,000,000 assuming full warrant exercise. Univest Securities acts as placement agent on a reasonable best-efforts basis, earning a 7% fee, with expected net proceeds of about $3.59 million before general corporate use including working capital, operating expenses, capex, acquisitions, and business development.
Operations run through PRC subsidiary Haoxi Beijing, making the structure and cash flows subject to Chinese regulatory, foreign investment, data security, CSRC filing and HFCA Act–related risks, which could impair the value or trading of the shares. For the year ended June 30, 2025, the company reported $32.80 million in revenue and net income of $3,876,680. The company does not expect to pay dividends in the foreseeable future and qualifies as both an emerging growth company and a foreign private issuer, allowing reduced U.S. reporting requirements.
Haoxi Health Technology Ltd. is offering 9,000,000 Class A ordinary shares at $0.25 per share and 16,999,998 pre-funded warrants (exercisable into up to 176,034,979 Class A shares), for gross proceeds of up to $6,455,799.51. The Pre-Funded Warrants have a $0.0026 exercise price and are exercisable upon issuance. The placement agent is Univest Securities, LLC. Pro forma net proceeds, assuming full exercise, are approximately $5.93 million. The offering is subject to PRC filing requirements under the CSRC Overseas Listing Trial Measures; the company says it will file with the CSRC within three working days after completion. The prospectus highlights risks tied to PRC regulatory developments, data/security rules, and potential HFCA Act delisting triggers tied to PCAOB inspection access. Key reported 2025 results: revenue $32.80 million and net income $3,876,680. Shares outstanding prior to offering: 58,753,028 Class A and 690,800 Class B (as of May 11, 2026).
Haoxi Health Technology Limited is offering up to $80,000,000 of its Class A Ordinary Shares through an at-the-market program with Aegis Capital Corp. acting as sales agent or principal. Aegis will sell shares on Nasdaq at prevailing prices and receive a 2.5% commission on gross proceeds. Based on a reference price of $1.56, Class A shares outstanding could rise from 58,753,028 to 110,035,079, which would significantly dilute existing holders.
The company plans to use net proceeds for general corporate purposes, including working capital, operating expenses, capital spending, potential acquisitions and business development. Haoxi is a Cayman Islands holding company whose operations run through its PRC subsidiary, Haoxi Beijing, an online marketing solutions provider focused on healthcare advertisers, which generated $32.80 million of revenue and net income of $3,876,680 for the year ended June 30, 2025.
The filing highlights substantial legal and operational risks tied to doing business in China, including evolving foreign investment, data security and CSRC overseas listing rules that could limit offerings or even render the shares worthless. It also notes potential HFCA Act delisting risk if PCAOB access to the auditor were ever restricted, PRC constraints on moving cash out of China, the absence of planned dividends, emerging growth and foreign private issuer status, and an auditor report expressing substantial doubt about the company’s ability to continue as a going concern.